GlaxoSmithKline Pty Ltd / Roche Products Pty Ltd / Medical Oncology Group Australia / /
Country
Australia / /
Facility
Cambridge University / /
Holiday
Commonwealth Day / /
IndustryTerm
treatment of breast cancer / treatment of metastatic breast cancer / treatment for breast cancer / treatment algorithms / Breast cancer treatment / /
MedicalCondition
early HER2+ breast cancer / Stakeholder meeting statement Breast cancer / cancer / brain metastases / disease / Late Stage Metastatic Breast Cancer / metastatic disease / metastatic breast cancer / metastatic HER2+ breast cancer / locally advanced HER2+ breast cancer / HER2-positive metastatic breast cancer / breast cancer / /
MedicalTreatment
adjuvant chemotherapy / chemotherapy / radiotherapy / drug therapies / drug therapy / surgery / chemotherapies / /
Organization
National Health and Medical Research Council / Cambridge University / Pharmaceutical Benefits Advisory Committee / Cancer Council Australia / Department of Health / American Society of Clinical Oncology / /
Stakeholder meeting statement Breast cancer treatment with anti-human epidermal growth factor receptor 2 (anti-HER2+) monoclonal antibody drugs A stakeholder meeting was held on 28 May 2014 to discuss how the treatment